Monitor for Form 4 filings confirming option exercises; minimal selling suggests no immediate concern, but watch for future patterns. The $0 acquisitions indicate equity compensation activity, which may lead to modest dilution.
CRBU drugs
CRBU drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 24 $2.14entry
- T+1 · 9mo ago −8.88%α −9.71% · $1.95
- T+5 · 9mo ago −17.76%α −16.73% · $1.76
- T+20 · 8mo ago −14.95%α −9.97% · $1.82
- T+60 · 6mo ago −7.94%α −14.69% · $1.97
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two C-suite executives at Caribou Biosciences, the Chief Business Officer and Chief Medical Officer, sold shares worth approximately $15.7K in the past week. Both also acquired 45,000 and 55,000 shares, respectively, at $0, likely through option exercises or grants. The net activity reflects minimal monetary selling, suggesting routine portfolio management rather than a negative signal.
Key Financial Metrics
Key Facts
- Chief Business Officer Khan Ruhi Ahmad sold 6,938 shares for $13,598.48 at $1.96 per share on 2026-02-24
- Chief Medical Officer Tina M. Albertson sold 1,066 shares for $2,089.36 at $1.96 per share on 2026-02-24
- Both executives acquired large blocks of shares (45,000 and 55,000) at $0 on 2026-02-20, likely via option exercise or vesting
- Total net proceeds from sales: ~$15,688
- All activity occurred within a 7-day window, indicating a coordinated or scheduled transaction period
Financial Impact
$15,688 in net insider selling
Risk Factors
- Potential for increased insider selling if negative catalysts emerge
- Dilution from exercised options or new grants
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (4 trades, 7d window) | cluster-CRBU-1771984487082 |
Track record
13 reports on CRBU
3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +28.02% at T+20 after the Oct 6, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 5, 202611d ago 8-K Bearish 7/10 Entry $0.4487 Now $0.3530 +21.33% settles Dec 7
- Oct 6, 20265w ago 8-K Bearish 7/10 Entry $0.6174 to $0.4444 Now $0.3530 +42.82% ▲ +28.02% +26.68% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $1.34 to $0.5190 Now $0.3530 −73.66% ▼ −61.27% −60.71% vs SPY
- Jun 11, 202622w ago 8-K Bullish 6/10 Entry $1.66 to $1.94 Now $0.3530 −78.73% ▲ +16.87% +14.98% vs SPY
- Jun 11, 202622w ago Press Release Bullish 7/10 Entry $1.66 to $1.94 Now $0.3530 −78.73% ▲ +16.87% +14.98% vs SPY
- Jun 5, 202623w ago DEFA14A Neutral 2/10 Entry $1.84 to $1.83 Now $0.3530 −80.82% ▼ −0.54% −2.17% vs SPY
- Apr 24, 202629w ago DEFA14A Neutral 3/10 Entry $2.13 to $2.16 Now $0.3530 −83.43% ▲ +1.41% −3.55% vs SPY
- Mar 5, 202636w ago 8-K Mixed 5/10 Entry $1.82 to $1.95 Now $0.3530 −80.60% ▲ +7.14% +9.19% vs SPY
- Mar 5, 202636w ago Press Release Mixed 6/10 Entry $1.82 to $1.95 Now $0.3530 −80.60% ▲ +7.14% +9.19% vs SPY
- Feb 28, 202637w ago Institutional Cluster Neutral 5/10 Entry $1.84 to $1.72 Now $0.3530 −80.82% ▼ −6.52% +1.42% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers